Patients should monitor their symptom patterns and discuss timing adjustments with their healthcare provider if side effects are limiting treatment adherence
In the next year, we will have the study to show whether it makes sense to give finerenone to protect the kidney in people with type 1 diabetes and CKD. Other trials of note include Remodel T1D and SUGARNSALT, but neither is sponsored by a drug company
Or perhaps youve heard conflicting information about which one works better for weight loss
The short answer: some lean mass loss occurs, as it does with any caloric deficit, but the proportion is better than diet-alone approaches
In the landmark SURPASS-2 clinical trial, Mounjaro achieved A1C reductions of up to 2.3% versus 1.9% for injectable semaglutide, while producing approximately 2.5 times greater weight loss (12.4 kg vs 6.2 kg)
Results vary based on calorie intake, food quality, metabolism, and lifestyle